Philip Philip
Overview
Explore the profile of Philip Philip including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
1350
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Alvarez J, Shi Q, Dasari A, Garcia-Aguilar J, Sanoff H, George T, et al.
BMC Cancer
. 2024 Jul;
24(1):901.
PMID: 39060961
Background: Recent data have demonstrated that in locally advanced rectal cancer (LARC), a total neoadjuvant therapy (TNT) approach improves compliance with chemotherapy and increases rates of tumor response compared to...
2.
Nowak J, Twombly T, Ma C, Shi Q, Haruki K, Fujiyoshi K, et al.
J Clin Oncol
. 2024 Jun;
42(24):2853-2859.
PMID: 38889377
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or...
3.
Tempero M, Pelzer U, OReilly E, Winter J, Oh D, Li C, et al.
J Clin Oncol
. 2022 Dec;
41(11):2007-2019.
PMID: 36521097
Purpose: This randomized, open-label trial compared the efficacy and safety of adjuvant -paclitaxel + gemcitabine with those of gemcitabine for resected pancreatic ductal adenocarcinoma (ClinicalTrials.gov identifier: NCT01964430). Methods: We assigned...
4.
Ryan C, Saif A, Rocha F, Philip P, Hernandez J, Ahmad S, et al.
Ann Surg Oncol
. 2022 Dec;
30(3):1302-1304.
PMID: 36474095
No abstract available.
5.
Strosberg J, El-Haddad G, Al-Toubah T, Reidy D, Ziv E, Mahvash A, et al.
J Nucl Med
. 2021 Sep;
PMID: 34556527
No abstract available.
6.
Lou E, Xiu J, Baca Y, Nelson A, Weinberg B, Beg M, et al.
Cells
. 2021 Jun;
10(6).
PMID: 34063999
The molecular heterogeneity of is well established, with a pool of variants comprising >75% of all known mutations; this pool includes mutations in classic codons 12, 13, and 61, as...
7.
Eng C, Chen E, Rogers J, Lewis M, Strosberg J, Thota R, et al.
JCO Oncol Pract
. 2021 Feb;
17(10):607-614.
PMID: 33534616
Despite efforts to enhance enrollment and the merger of national cooperative groups, < 5% of patients with cancer will enroll into a clinical trial. Additionally, clinical trials are affected by...
8.
Lum L, Thakur A, Choi M, Deol A, Kondadasula V, Schalk D, et al.
Oncoimmunology
. 2020 Sep;
9(1):1773201.
PMID: 32939319
Purpose This was a phase I/II adoptive T cell trial in 7 locally advanced and metastatic pancreatic cancer patients using 3-8 infusions of anti-CD3 x anti-EGFR bispecific antibody armed activated...
9.
Rutledge B, Jan J, Benjaram S, Sahni N, Naylor P, Philip P, et al.
J Gastrointest Cancer
. 2019 Dec;
51(3):972-979.
PMID: 31792736
Purpose: Surveillance, treatment, and outcomes for African-American (AA) populations with hepatocellular carcinoma (HCC) remain under evaluated. This study evaluated demographics, surveillance, therapy, and outcomes for a predominately AA population. Methods:...
10.
Fuchs C, Doi T, Jang R, Muro K, Satoh T, Machado M, et al.
JAMA Oncol
. 2018 Mar;
4(5):e180013.
PMID: 29543932
Importance: Therapeutic options are needed for patients with advanced gastric cancer whose disease has progressed after 2 or more lines of therapy. Objective: To evaluate the safety and efficacy of...